In this week’s video, Dr. Durie explains what a "BEAT" is, and how it is similar to a BiTE.

BOTTOM LINE:
A BEAT is a bispecific antibody that binds T-cells to myeloma cells.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Transcript:

This week's "Ask Dr. Durie" comes from. A patient who wants to know, "What is a BEAT?" Well, this is a new question that comes from a press release just a few weeks back, indicating that a BEAT was going to be tested in multiple myeloma.

So, it turns out that a BEAT is very similar to a BiTE, that we've been talking about for a couple of years or so now. They are basically different acronyms for the same thing.  A BEAT is a bispecific engager for a monoclonal antibody to link to a T cell, "B-E-A-T." A BiTE is also a bispecific engager for T cells, it just does not include the "A" for the antibody. It doesn't reference the antibody.  So, basically, a BEAT and a BiTE are actually the exact same type of thing.

The BEAT came into the news because a company called Glenmark announced that they had received orphan designation for a new BEAT in clinical trials. This is GBR 1342.
 
And so, what is GBR 1342? It's a BEAT, which is an antibody linking CD38, the surface receptor on the myeloma to CD3, the surface on the T cells. And so, this pulls in the T cells close to the myeloma and enhances the anti-myeloma effect of the CD38 antibody. And so, this is a double hit against the myeloma. And, this is definitely a very promising technology.
 
In the case of the GBR 1342, the studies are quite early in the phase I to II testing period. For this, the BEAT is given by a 24-hour infusion. These types of agents tend to have a short half-life, so they do need to be administered by an infusion. In this case, twice a week.  And so, the preliminary results are promising.
 
And the BOTTOM LINE, in this case, is that a BEAT is like a BiTE. And the new BEAT, GBR 1342, is promising and we'll be looking forward to results in the coming months. 


Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie founded and now serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

 

Previous Post
What is the CANDOR trial?
Next Post
Is it possible for bone lesions to progress even when all other tests look good?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.